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Strengths and limitations of this study
 ► This study uses a novel approach by providing re-
gional colorectal cancer multidisciplinary teams 
(MDTs) with data and, with their input, developing 
educational interventions to minimise any variation 
seen in order to optimise outcomes.
 ► The strength of this study includes evaluating vari-
ation in the management and outcomes of patients 
with colorectal cancer by combining routinely col-
lected clinical datasets and novel information on 
aspects of care not currently quantifiable through 
existing datasets.
 ► The study will facilitate implementation of guidelines 
such as routine screening for Lynch syndrome and 
deficient mismatch repair status.
 ► The potential of the study is limited by the extent of 
engagement from regional colorectal cancer MDTs.
AbStrACt
Introduction Although colorectal cancer outcomes in 
England are improving, they remain poorer than many 
comparable countries. Yorkshire Cancer Research has, 
therefore, established a Bowel Cancer Improvement 
Programme (YCR BCIP) to improve colorectal cancer 
outcomes within Yorkshire and Humber, a region 
representative of the nation. It aims to do this by 
quantifying variation in practice, engaging with the 
colorectal multidisciplinary teams (MDTs) to understand 
this and developing educational interventions to minimise 
it and improve outcomes.
Methods and analysis Initially, routine health datasets 
will be used to quantify variation in the demographics, 
management and outcomes of patients across the 
Yorkshire and Humber region and results presented to 
MDTs. The YCR BCIP is seeking to supplement these 
existing data with patient- reported health- related quality 
of life information (patient- reported outcome measures, 
PROMs) and tissue sample analysis. Specialty groups 
(surgery, radiology, pathology, clinical oncology, medical 
oncology, clinical nurse specialists and anaesthetics) 
have been established to provide oversight and direction 
for their clinical area within the programme, to review 
data and analysis and to develop appropriate educational 
initiatives.
Ethics and dissemination The YCR BCIP is aiming to 
address the variation in practice to significantly improve 
colorectal cancer outcomes across the Yorkshire and 
Humber region. PROMs and tissue sample collection and 
analysis will help to capture the information required to 
fully assess care in the region. Engagement of the region’s 
MDTs with their data will lead to a range of educational 
initiatives, studies and clinical audits that aim to optimise 
practice across the region.
IntroduCtIon
Colorectal cancer is a common disease in 
the UK with over 41 000 people diagnosed 
each year and 16 000 people dying from it. 
Although survival rates have improved over 
time, they continue to lag behind those 
attained by many economic neighbours1 and 
so developing educational interventions to 
improve outcomes is a priority.
Some potential explanations for these 
survival differences include quality of care 
and access to services. For example, local 
recurrence and survival rates in rectal cancer 
are related to the quality of the surgical resec-
tion2 so improving surgical quality is likely 
to improve outcomes. Likewise, ensuring 
gold- standard diagnostic, staging and multi-
disciplinary care across all aspects of the 
patient pathway have a demonstrable impact 
on outcomes3 while screening for Lynch 
syndrome and deficient mismatch repair 
will enable more effective management of 
patients.
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Other countries have acknowledged these relation-
ships and taken steps to improve standards. For instance, 
in the early 1990s, Norway recognised there was a huge 
variation in local recurrence rates depending on which 
surgeon operated.4 In response, they initiated a training 
programme to quantify variation and improve the quality 
of surgery. This strategy was a success, reducing local 
recurrence and improving overall survival.5 As a result 
similar programmes in other countries, including the UK, 
were established with equally positive outcomes including 
lower postoperative mortality6 and better survival,3 7 lower 
permanent stoma7 and local recurrence rates,8 better 
preoperative staging,9 improved selection of patients for 
non- surgical treatment9 and the need for less emergency 
surgery.3
While these programmes have undoubtedly had a posi-
tive impact, variations in management remain and partic-
ularly so in the UK.10 11 Although survival rates in the UK 
have improved, the gap to rates attained in comparable 
countries1 have not closed. A better understanding of 
what is driving these variations will help to target educa-
tional interventions to improve care.
Yorkshire Cancer Research (YCR) is a charity whose aim 
is to ensure that more people of Yorkshire and Humber 
‘avoid, survive and cope’ with cancer and, by 2025, they 
intend to have reduced cancer deaths in the region by 
2000 per year.12 As part of their strategy to achieve this, 
they have recently funded the Bowel Cancer Improvement 
Programme (YCR BCIP). This initiative builds on the 
experience gained from English National programmes9 13 
and extends the approach of those successful programmes 
completed in Scandinavia.3 5 8 It centres on the collection 
and analysis of robust colorectal cancer data to examine 
practice across the region, ensuring the multidisciplinary 
teams (MDTs) managing the disease engage with these 
data and agree on areas for improvement. Educational 
interventions or other strategies can then be developed 
and implemented to ensure optimal practice is achieved.
This protocol paper gives an overview the YCR BCIP 
study, which has the following aims:
1. Quantify and report the variation in the demograph-
ics, management and outcomes of the region’s patients 
with colorectal cancer using
a. Routinely collected clinical datasets.
b. New information on aspects of care not currently 
quantifiable through existing datasets (eg, patient- 
reported outcome measures (PROMs), the molecu-
lar subtyping of the disease and the quality of radi-
ology, pathology and surgery).
2. Determine how outcomes from the Yorkshire and 
Humber region compare to the rest of England.
3. Provide the Yorkshire and Humber region colorectal 
MDTs with these data and, with their input, develop 
educational interventions to minimise any variation 
seen in order to optimise outcomes.
4. Facilitate implementation of guidelines such as rou-
tine screening for Lynch syndrome and deficient mis-
match repair status.
5. Evaluate improvement in outcomes over the study 
period.
MEthodS And AnAlySIS
Setting
The Yorkshire and Humber region of the UK has a popu-
lation of approximately 5.7 million with around 3300 
colorectal cancer diagnoses a year, amounting to just 
over 10% of diagnoses in England. Patients diagnosed 
with colorectal cancer in the region are managed by 16 
different MDTs. These operate across 14 National Health 
Service (NHS) trusts, which provide health services for 
particular geographical areas of the region which exhibit 
a range of workloads, ranging between approximately 120 
and 390 cases a year (4%–12% of the regional workload). 
Patients within the geographical areas covered by each 
trust exhibit a variable range of demographic features 
such as socioeconomic deprivation and comorbidity.14
Programme overview
YCR BCIP will examine routinely collected NHS data 
and, subject to patient consent, additional data collected 
specifically for the programme. Baseline performance 
outcomes for each MDT from across the region will be 
assessed. The knowledge will be fed back to each MDT 
and a programme of educational interventions devel-
oped based on the performance outcomes. The process 
will be iterative as outlined in figure 1. The programme 
commenced on 1 April 2016 and will run until 31 March 
2021.
Following a regional meeting of MDT representatives 
to discuss, plan and agree to programme participation 
held in June 2016, six specialty groups were initially 
established. The remit of these groups is to provide over-
sight and direction for their clinical specialty within the 
programme, to review data and analyses and to develop 
appropriate educational initiatives. The six groups 
focused on the main clinical disciplines involved in the 
MDT; surgery, radiology, pathology, clinical oncology, 
medical oncology and specialist nursing. Group member-
ship was drawn from all of the region’s MDTs and an 
individual identified from each to to act as a coordinator 
between the research team and MDT. The need for a 
separate anaesthetics workstream was subsequently iden-
tified and introduced. A lead clinician was also identified 
for each discipline, having the responsibility to coordi-
nate educational events, gather opinion on best practice, 
formulate consensus views and drive agreed initiatives 
into routine clinical care across the region.
data sources
Although broad ranging, it was recognised that the 
routine colorectal cancer data available are not sufficient 
to quantify all aspects of care robustly. While routine data 
provide good information available on ‘hard’ outcomes 
such as which operation was undertaken or survival time, 
there is a lack of information on what this really means to 
the individual concerned and the quality of that survival. 
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Figure 1 Yorkshire Cancer Research Bowel Cancer Improvement Programme process and study design. MDT, 
multidisciplinary team; PROMs, patient- reported outcome measures.
This precludes the production of the rich intelligence the 
MDTs want to fully understand variation in care. There-
fore, data collated in YCR BCIP will come from three 
main sources:
Existing population-based datasets
Consisting of routine NHS datasets providing both 
regional data (around 3300 cases per year) and compar-
ative national data (around 28 700 cases per year) on 
patient and tumour characteristics, treatment choices, 
diagnosis pathways and patient outcomes. All patients 
diagnosed with a first primary colorectal cancer (Inter-
national Statistical Classification of Diseases and Related 
Health Problems 10th Revision (ICD-10) C18–C20) in 
England from 1 January 2005 to the end of the study and 
registered in the National Cancer Registration and Anal-
ysis Service (NCRAS)15 will be eligible.
 Direct PROMs and tissue collection
Consisting of regional PROMs data collected directly 
from patients via a questionnaire on health- related quality 
of life (at both the time of diagnosis, before primary treat-
ment if possible and again at 12 months postdiagnosis) 
and molecular testing of tumour and tumour- associated 
normal mucosal tissue samples.
All MDTs in the region have been invited to partici-
pate in this element of the YCR BCIP. Every patients with 
colorectal cancer (ICD-10 C18–C20) are eligible if they 
are considered suitable for treatment, English language 
literate, aged at least 18 years old and with capacity to give 
informed consent. Participants will be asked to consent to 
the study prior to commencement of primary treatment 
or following an emergency intervention.
 Audit and survey data
Consisting of unlinked anonymised data collected from 
clinicians at regional MDTs in the form of an audit or 
a clinician survey. The exact nature of these shall be 
identified by each clinical discipline depending on the 
needs and availability of existing data. However, they 
are expected to include but are not limited to: an audit 
on surgical quality using specimen photographs, audits 
assessing the completeness in the recording of pathology 
and radiology reports, an audit on the methods of lymph 
node retrieval and clinican surveys assessing the manage-
ment of patients in the oncological, surgical and aesthetics 
settings. All clinicians who are members of regional MDTs 
as part of the discipline being assessed will be eligible to 
participate.
data collection
 Existing population-based datasets
The YCR BCIP seeks to make maximum use of routine 
NHS datasets and these are brought together in the UK 
Colorectal Cancer Intelligence Hub16 where data from the 
NCRAS are linked to other datasets relevant to colorectal 
cancer to provide the richest data possible and enable 
analysis of the full cancer pathway. These include, but are 
not limited to: Hospital Episode Statistics (HES), Radio-
therapy Dataset, Systematic Anti- Cancer Therapy Datatset 
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Figure 2 Process for the patient- reported outcomes measures study.
and Routes to Diagnosis. To provide a baseline, these data 
will cover the period from 1 January 2005 to the start of 
the programme and be routinely collected until the end 
of the study to assess changes throughout it.
All patients in the NCRAS data will be assigned an 
MDT using the HES procedure closest to the patient’s 
diagnosis date. If no procedure is found, the closest inpa-
tient or outpatient appointment to the diagnosis date 
at a hospital with a colorectal MDT is used. Those not 
assigned an MDT (<1% of patients) will be excluded from 
analyses. The assigned MDT will be assumed to have been 
responsible for the patient’s management and treatment 
options.
 Direct PROMs and tissue collection
This research project is adopted by the NIHR Yorkshire 
and Humber Clinical Research Network and therefore 
recruitment will be undertaken across the region by 
network research and clinical staff working collabora-
tively. Recruitment will run over a 30- month period.
Eligible patients will be identified and approached in 
two ways.
1. Identified via the MDT and informed about the study 
by consultant letter sent out with their appointment 
letter for the primary preassessment clinic visit . Where 
possible, patients will be approached about the study 
at this clinic appointment. Patients missed at this ap-
pointment will be contacted at the earliest convenient 
time point and informed about the study.
2. Identified by their NHS clinical team if they present as 
an acute admission (eg, with a bowel obstruction) and 
informed about the study by their clinical team follow-
ing the emergency intervention (eg, surgery).
Participants will have the option of completing a PROMs 
questionnaire either online PROMs using the University 
of Leeds secure questionnaire administration system 
QTool,17 accessed via the study website, ( www. YCRBCIP. 
leeds. ac. uk) or on paper PROMs with a prepaid return 
envelope. They will be asked to complete the question-
naire as soon as possible after consenting. This may be 
completed while attending hospital at the time of consent 
or later at home. Just prior to the 12- month follow- up ques-
tionnaire, the patient status will be checked via NCRAS to 
confirm that the patient is still alive. Patients will then be 
sent an email/letter 12 months postdiagnosis by the YCR 
BCIP research team, inviting them to complete PROMs 
again (on paper or online according to patient prefer-
ence). At both time points, reminder letters or emails will 
be sent at 2 weeks and followed up 2 weeks later (if no 
response) with the questionnaire being resent with the 
reminder letter. The process is outlined in figure 2.
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Participants will be asked to complete a range of vali-
dated generic, cancer- specific and colorectal cancer- 
specific PROMs in addition to sociodemographic 
characteristics. Content has been informed by: clinical 
relevance, opinion of service users, overall length and 
participant burden,18 reviews of questionnaires measuring 
quality of life in patients with colorectal cancer19–23 and 
UK recommendations for the core outcomes set for trials 
in colorectal cancer surgery.24
The questionnaire comprises four sections at baseline 
and five sections at follow- up. The questionnaire is esti-
mated to take 30–35 min to complete.
Your overall health and quality of life (both time points)
 ► European Organisation for Research and Treat-
ment of Cancer (EORTC) Quality of Life Question-
naire- C30, the colorectal cancer- specific module and 
items from the prostate, endometrial and cervical 
cancer modules.25–29
 ► EuroQol- Five Dimension- Five Level Group.30
Your everyday life and well-being (both time points)
 ► Social Difficulties Inventory-21.31 32
 ► The Short Warwick- Edinburgh Mental Well- being 
Scale.33 34
Managing your health (both time points)
 ► Self- efficacy for Managing Chronic Disease.35
 ► The Brief Illness Perceptions Questionnaire.36
Questions about you (both time points)
 ► Self- reported sociodemographic and clinical details.
The financial cost of cancer (second time point only)
 ► A questionnaire developed in- house based on one 
used in the electronic Patient- reported Outcomes 
from Cancer Survivors (ePOCS) study.37
The tissue samples to be collected for this study are:
1. Excess pretreatment, diagnostic biopsy tumour tissue.
2. Excess tissue following surgical resection (tumour and 
tumour- associated normal mucosal tissue).
3. Excess tumour tissue following the biopsy or resection 
of distant metastases.
The tissue samples will be formalin fixed and paraffin 
wax embedded as per the routine histopathology proce-
dures at the patients’ hospital. Tissue blocks will be used 
for any routine clinical diagnostic procedures required by 
the hospital before being sent to Pathology at the Univer-
sity of Leeds, and will be available to return to the hospital 
for further clinical testing if required.
Based on the number of diagnoses per year, there is 
potential to consent approximately 8250 patients from 
sites across the region over a 30- month recruitment 
period. However, due to eligibility restrictions, consent by 
MDT and by individuals, administrative/practical issues 
and staggered site recruitment start dates, the partici-
pation rate is likely to be less. Using estimates based on 
previous studies,38 39 the consent rate is estimated to be 
around 42% and the an attrition rate of approximately 
35% at the 12 months follow- up point, giving a sample 
size of at least 1200. This will provide MDTs with a compre-
hensive descriptive profile of their patients in terms of 
quality of life outcomes; more complex analyses will be 
undertaken if sufficient numbers are accrued.
 Audit and survey data
Audit data will be limited to data that are collected as 
part of routine patient care. For example, anonymised 
MRI scans that have been performed as a part of patient 
care may be used as part of an educational training initia-
tive. No specific recruitment will be performed for these 
data as only anonymised data used as part of routine 
patient care will be used. Clinicians at regional MDTs will 
complete surveys anonymously online using www. online-
surveys. ac. uk (formally Bristol Online Survey). These 
surveys will be used to assess clinical practice and patient 
management. For example, a survey regarding the use of 
adjuvant chemotherapy will be used to compare regional 
practice to the most recent evidence basis and used to 
inform a regional guideline for the treatment of these 
patients.
Regional MDT clinicians will be invited to complete 
the online surveys via email and through specialty group 
meetings.
Consent
 Existing population-based datasets
The data are derived from the patient- level information 
collected by the NHS, as part of the care and support of 
patients with cancer. NCRAS has a specific legal permis-
sion to collect this information without the need to seek 
consent, however, patients can ask NCRAS to remove 
their details from the cancer registry at any time. Access 
to cancer registration data and the other routine health 
datasets used in this study is controlled by the Public 
Health England (PHE) Office for Data Release, and is 
only approved for permitted medical purposes.15 This 
work is covered by a data sharing contract with PHE 
(ODR1516_369).
 Direct PROMs and tissue collection
Identified patients will be provided with full study infor-
mation (written and verbal) by specialist research nurses 
or Clinical Nurse Specialists who have undergone Good 
Clinical Practice training to assure the rights, safety 
and well- being of research participants are protected.40 
Written consent may be taken at the time of this approach 
but patients will be given up to a week to think about 
study participation. Patients who wish to join the study 
will be asked to read, complete and sign a consent form, 
including their contact details name, address and/or 
email address. The person taking consent will also record 
the patient’s date of birth, NHS number and gender. 
Patients must consent to both PROMs participation and 
tissue collection to be included in the study.
Patients are asked to consent to their clinical team being 
informed in the event that clinically relevant laboratory 
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Table 1 Measures of patient characteristics, treatment 
measures and outcomes to analysed and the corresponding 
data source
Data source
Existing 
population- 
based 
datasets
Direct 
PROMs 
and tissue 
collection
Audit 
and 
survey 
data
Patient and tumour 
characteristics
  Age and sex NCRAS PROMs
  Ethnicity NCRAS PROMs
  Height and weight PROMs
  Comorbidity NCRAS PROMs
  Socioeconomic status NCRAS PROMs
  Stage and site NCRAS
  Method of admission NCRAS
Treatment variation
  Surgical resection rate HES
  Quality of surgery Audit
  Abdominoperineal 
excision rate
HES
  Use of adjuvant and 
palliative chemotherapy
SACT Survey
  Use of neoadjuvant 
radiotherapy
RTDS
  Use of laparoscopic 
surgery
HES
  Emergency care 
procedures
HES Survey
  Practice of anaesthetics Survey
  Quality of MRI reporting Audit
  Quality of CT imaging Audit
  Liver metastases 
resection rate
HES
  Nodal yields and retrieval 
methods
NCRAS Audit
Outcomes
  30- day postoperative 
mortality
NCRAS
  1–5 years overall and net 
survival
NCRAS
  18- month postoperative 
stoma rate
HES
  Postoperative hospital 
stay
HES
  Emergency readmission 
rates
HES
  Overall health and quality 
of life
PROMs
  Everyday life and well- 
being
PROMs
  Self- efficacy for managing 
chronic disease
PROMs
  Financial cost of cancer PROMs
Continued
results are found. This includes the possibility of hered-
itary conditions identified through tumour testing, ‘for 
example, Lynch syndrome or deficient mismatch repair 
status’. These will be confirmed through routine NHS 
Clinical Genetics testing after counselling following 
referral from the local clinical teams with no germline 
testing taking place through the programme.
 Audit and survey data
No specific consent will be needed for these data as only 
anonymised data used as part of routine patient care will 
be used, for example, specimen photographs or scans will 
have all identifiers removed. Consent for the surveys will 
be implied when the clinician completes a survey that 
they have been invited to.
data linkage
While initially the existing population datasets and direct 
PROMs and tissue collection will be analysed separately, 
these will subsequently be linked together through the 
UK Colorectal Cancer Intelligence Hub using name, 
NHS number and date of birth. This will provide addi-
tional patient characteristics for analysis of the PROMs 
and tissue data.
Analysis
 Existing population-based datasets
Baseline assessments of care in the region are to be 
performed on individuals diagnosed with colorectal 
cancer in Yorkshire and Humber, enabling comparison 
between teams in the region and with national data.14 
Initially, this includes using descriptive analysis and statis-
tical methods such as regression modelling, survival anal-
ysis and funnel plots41 comparing the following data: 
demographic characteristics, tumour characteristics, 
surgery and oncology management and short and long- 
term outcomes.
Some analyses will be rerun periodically over the course 
of the programme to evaluate the impact on outcomes 
of specific educational interventions. The measures to be 
analysed and the sources of these can be found in table 1.
 Direct PROMs and tissue collection
Descriptive statistics will be used to report the question-
naire results and assess the quality of life outcomes of the 
participants. Following data linkage, the outcomes will 
be analysed according to stage of disease, treatment type, 
comorbidity, age, ethnic and sociodemographic group 
(and other relevant variables). These descriptive analyses 
will identify potential relationships of interest, which can 
be investigated further. Regression modelling will be used 
to investigate associations among the different types of 
variables to identify statistically and clinically significant 
risk factors and predictors of outcomes. In order to be 
robust, analyses will require appropriate adjustment for 
casemix and other confounding factors and may require 
more complex techniques, such as the modelling of hier-
archies within the data (multilevel modelling), post hoc 
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Data source
Existing 
population- 
based 
datasets
Direct 
PROMs 
and tissue 
collection
Audit 
and 
survey 
data
  Urinary function and 
faecal incontinence
PROMs
  Sexual functioning PROMs
  Lower anterior resection 
syndrome
PROMs
  Molecular subtyping Tissue
HES, Hospital Episode Statistics; NCRAS, National Cancer 
Registration and Analysis Service; PROMs, patient- reported outcome 
measures; RTDS, radiotherapy dataset; SACT, systemic anticancer 
therapy dataset.
Table 1 Continued
weighting to overcome response bias and multiple impu-
tation of missing data.
Tissue samples removed at surgery or biopsy which are 
surplus to routine clinical requirements will be used by 
the research team for upfront testing of novel biomarkers. 
YCR BCIP will test for novel or rare potentially treatable 
targets via a range of molecular techniques. The immu-
nohistochemical markers of interest include, HER2, 
PTEN, PD-1 and PD- L1, amphiregulin and epiregulin, 
and immune system markers CD3 and CD8. The study 
will also undertake phenotype analysis by using high- 
resolution scanned images of tumours using novel algo-
rithms to identify improved prognostic and predictive 
markers of outcome. Next- generation sequencing and/
or pyrosequencing will be performed on any extracted 
DNA to identify tumours with specific gene hotspot muta-
tions including, KRAS, NRAS, BRAF, EGFR and PIK3CA. 
Other molecular markers linked to causation, outcome 
and response to therapy will also be investigated, for 
example, bacterial toxin carriage or fusobacterium 
nucleatum. Analysis of RNA expression levels of receptor 
ligands, such as amphiregulin and epiregulin, and HER2 
and HER3, may also be performed. The biomarkers will 
be linked to patient data (population based and PROMs) 
and undergo regression modelling to identify associations 
to understand how tumour biology influences outcomes, 
response and quality of life and how tumour biology can 
be influenced by lifestyle.
 Audit and survey data
The analyses of audit and survey data will be dependent 
clinical specialties involved and the nature of the data 
collected. For example, the completion of MRI scans for 
rectal cancer at an educational training initiative would be 
assessed by agreement coefficients and results of surveys 
will be analysed using descriptive statistics.
data safeguards
Participant recruitment will be undertaken by each trust 
involved in the study. Each research network site will 
allocate a study ID for potential participants. They will 
use a University of Leeds secure electronic transfer system 
every 2 weeks to inform the YCR BCIP research team of 
all recruitment activity. This will include the consented 
patients contact details, date of birth and NHS number 
to allow for follow- up and to ensure tissue blocks are 
appropriately labelled for tracking and data linkage. All 
subsequent participant contact will be undertaken by the 
central YCR BCIP team.
Storage of all hard copy documents will be in locked 
metal filing cabinets in research offices of the Univer-
sity of Leeds with secure access building controls. Tissue 
samples will be used and stored in a secure building with 
restricted access. Electronic data with pseudonymised 
(allocated ID number) patient information will be stored 
in a secure environment. These files will only be acces-
sible to relevant members of the study analysis team. 
Where temporary storage of sensitive data is required 
(eg, contact details for sending out repeat question-
naires), files will be accessible only to relevant members 
of the research team and not stored with any linked data. 
Members of the analysis team will not have access to any 
identifiable data. Hard copy data will be kept for 5 years 
following the end of the study (until 2026) for long- term 
follow- up.
development of educational interventions
The analyses will be disseminated and discussed by 
regional MDTs at events for each clinical discipline. 
Agreements of educational needs to improve care will be 
agreed along with any additional data capture and audit 
processes that teams agree are required. The process 
is repeated with ongoing data analyses to establish the 
improvements in management and outcomes that have 
occurred (figure 1). As YCR BCIP progresses, further 
work will be undertaken looking at other outcomes 
including, but not limited to, those related to screening, 
pathology and long- term outcomes.
Public patient involvement
Patients and carers were actively engaged through the 
PROMS working group to develop the design and content 
of the patient questionnaires, the patient information 
sheet and consent form. At the request of the patients 
and carers, additional questions were included around 
the financial impact of cancer and a specific request was 
made to EORTC to amend the EORTC colorectal module 
and add specific questions from other EORTC modules to 
understand side effects of cancer and cancer treatments. 
EORTC granted these specific amendments for this study. 
The electronic and paper copies of the final draft ques-
tionnaires were tested with patients attending a colorectal 
cancer follow- up clinic at one of the region hospitals. 
Modification to the layout of the questionnaires were 
made following the results of the testing. The testing gave 
an understanding of the length of time it took patients to 
complete the questionnaires. The PROMS working group 
will remain active throughout the length of the study; the 
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group will be kept apprised of recruitment levels and 
early results. It is expected that the patients will advise on 
the analysis and how the results are communicated to the 
regional clinical teams and wider audiences.
dISCuSSIon
The YCR BCIP study ambitiously aims to improve 
outcomes for patients with colorectal cancer across the 
Yorkshire and Humber region by in- depth analysis of 
existing and newly captured data, and by actively engaging 
local MDTs. In its initial stages, this will be done by demon-
strating the variation in the demographics, management 
and outcomes in the region using routine NHS datasets. 
However, given the limitations of what can be achieved 
with existing data, the YCR BCIP is collecting additional 
data to analyse alongside this with the purpose to better 
understand what is driving the observed variation.
The PROMs data will enrich other study data and 
allow for an ‘in- depth’ description of what life is really 
like for patients with colorectal cancer at diagnosis and a 
year later. At present, the patient voice is not ‘measured’ 
routinely as part of clinical practice, neglecting the impact 
of illness and treatment on the everyday lives of patients. 
YCR BCIP will change this with the integration of PROMs 
administration into clinical practice.39 The PROMs used 
in this study have been selected with input from experts 
in colorectal cancer and psychosocial care: patients, clin-
ical nurse specialists and doctors. Although the length of 
the questionnaire would not be feasible to administer in 
everyday practice, information on which PROMs provide 
the most meaningful data will be obtained. In the future, 
risk- stratified follow- up may incorporate clinical indica-
tors and key quality of life indicators to inform the best 
supportive care.42
Results from the tissue collection and testing could 
impact on treatment and follow- up decisions for the 
participating patients and, potentially, their families. For 
example, the results may indicate that a patient could 
benefit from a targeted treatment being tested through 
an open clinical trial if they develop an indication 
for further treatment, for example, Medical Research 
Council FOCUS4.43 Increased risks of having a hereditary 
condition may be identified, which has implications for 
the patient and their family.
The YCR BCIP is offering a novel approach to address 
the variation in colorectal cancer care across a large 
region of the UK. Engagement of the region’s MDTs with 
their data will lead to a range of educational initiatives, 
studies and clinical audits that aim to optimise practice 
across the region. It is planned that the outcomes of 
these will be presented to the relevant specialty group 
for review and to develop actions based on findings. The 
main limiting factor for the success of the study is that to 
understand the overall picture of colorectal cancer care 
and the ability to improve this in the region, relies on the 
extent of engagement from MDTs.
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